Global Brand Lead, Migraine
Cambridge, MA (Hybrid)
$233K/yr – $341K/yrSenior Level15+ years expFull time
Posted 5 days ago
Job Summary
Original Job Description
Ipsen
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in 88 countries.For more information, visit ipsen.com.Pauta exclusiva para México:Clave de Autorización COFEPRIS: 243300201B1962 CONSULTE A SU MÉDICO.
Marketing team
363
Employees
6.5K
Headquarters
Paris, Île-de-France, FRA
Founded
1987
Traffic Signals
Monthly Visitors
90.3K
Monthly Google Ads Budget
$0.0
Traffic Source Mix
Search
57.1%
Direct
32.9%
Referral
6.6%
Social
2%
Paid
1.1%
Headcount Trend
Current headcount: ~6.5K
Funding
Total Funding
$574.7M
Last Raise
12 months ago
Last Raise Amount
$545.6M
- 2025-03-19Post IPO Debt • $545.6M
- 2017-11-20Post IPO Equity • $29.1M
Recent News
Ipsen
ESMO 2025 : les données d’Ipsen enrichissent et élargissent son portefeuille de produits en R&D et commercialisés en Oncologie - Global
Oct 13, 2025
Boursorama
Ipsen: UBS réitère son conseil à achat
Oct 13, 2025
Monde des grandes écoles
Envie d’une carrière dans la pharma ? Ipsen vous offre des carrières sur-mesure - L’interview de Laurent Bertocchi
Sep 30, 2025
Boursorama
Ipsen et BioLabs Hôtel-Dieu décernent le Golden Ticket Ipsen 2025 à DETERA Therapeutics
Sep 26, 2025
La Tribune
Ipsen : Prises de bénéfices sur le turbo PUT 74U2S (+15.46%)
Sep 23, 2025
Boursorama
Ipsen : des données encourageantes pour IPN10200
Sep 22, 2025
Boursier.com
Ipsen : L'essai de Phase II LANTIC en esthétique démontre un profil clinique différencié à longue durée d'action, premier de sa classe pour l'IPN10200, permettant le lancement de l'étude de Phase III
Sep 22, 2025
GlobeNewswire
L’essai de Phase II LANTIC d’Ipsen en esthétique démontre
Sep 22, 2025
Investing.com France
L’IPN10200 d’Ipsen montre des résultats prometteurs dans un essai esthétique de phase II
Sep 22, 2025
Ipsen Pharma
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
Sep 22, 2025
Investing.com
Ipsen’s IPN10200 shows promising results in Phase II aesthetics trial
Sep 22, 2025
MarketScreener
Ipsen shares first aesthetic data for IPN10200 in phase II trial
Sep 22, 2025
Boursorama
Ipsen : le produit Bylvay approuvé au Japon dans une indication
Sep 19, 2025
Les Echos
Ipsen obtient le feu vert au traitement d'une maladie rare du foie au Japon
Sep 19, 2025
thefly.com
Ipsen announces Bylvay approval in Japan for pruritus associated with PFIC
Sep 19, 2025
Ipsen Pharma
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC
Sep 19, 2025
pharmaphorum
Regeneron drug on track to be second FOP treatment
Sep 18, 2025
FierceBiotech
Regeneron reports phase 3 win in ultrarare disease, bouncing back to spark race to FDA
Sep 17, 2025
L'Usine Nouvelle
Chez Ipsen, Christelle Huguet poursuit sa quête de découvertes dans les sciences appliquées
Sep 16, 2025
Boursier.com
Ipsen : objectifs en vue
Sep 15, 2025
MedCity News
Long Regulatory Saga for Intercept Pharma Liver Drug Ends a Decade After Speedy FDA Approval
Sep 12, 2025
pharmaphorum
Intercept pulls Ocaliva off the market in the US
Sep 11, 2025
PR Newswire UK
Health Canada Approves Bylvay™ (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille Syndrome
Sep 9, 2025
Canada NewsWire
Health Canada Approves Bylvay™ (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille Syndrome Français
Sep 9, 2025
BioSpace
Health Canada Approves Bylvay™ (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille Syndrome
Sep 9, 2025
FierceBiotech
Chutes & Ladders—Merck KGaA lands new R&D chief
Sep 5, 2025
ABC Bourse
Ipsen en pleine ascension face à une barrière technique majeure
Sep 4, 2025
BFM Bourse
IPSEN : Encore du potentiel
Sep 4, 2025
La Tribune
Ipsen : Correction technique attendue
Sep 3, 2025
PharmiWeb
Parabilis Medicines Appoints Fawzi Benzaghou, M.D., as Chief Medical Officer
Sep 3, 2025
citybiz
Parabilis Medicines Appoints Fawzi Benzaghou, M.D., as Chief Medical Officer
Sep 3, 2025
Ipsen Pharma
IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2025
Sep 2, 2025
Ipsen Pharma
IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2025
Aug 29, 2025
FierceBiotech
Zydus' phase 3 liver disease win tees up filing to challenge Gilead and Ipsen
Aug 29, 2025
Research and Markets
Cholestatic Pruritus Global and Regional Markets, 2023-2025 & 2025-2035 | Competition Intensifies as Pharma and Biotech Firms Pursue Partnerships, M&A, and Novel Therapy Development
Aug 27, 2025
PR Newswire
Women In Bio Names Gina Ford First-Ever CEO
Aug 27, 2025
Ipsen Pharma
Ipsen - July 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
Aug 27, 2025
L'Usine Nouvelle
Servier, Sanofi, Ipsen... Les laboratoires français décrochent trois nouvelles autorisations en Europe pour des traitements contre le cancer
Aug 25, 2025
L'Usine Nouvelle
Made in France : Ipsen, d'une petite officine au troisième laboratoire pharmaceutique français
Aug 23, 2025
EIN Presswire
Primary Biliary Cholangitis Therapeutics Global Market Report 2025| Business Growth, Current and Future Trends till 2029
Aug 22, 2025
Les Echos
Ipsen relève ses objectifs 2025, hausse du CA au S1
Aug 19, 2025
Ipsen Pharma
IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2025
Aug 19, 2025
Les Echos
Ipsen, son médicament phare, somatuline, bénéficie d'un sursis, l'annonce de nouveaux relais de croissance est attendue au second semestre
Aug 14, 2025
ABC Bourse
Ipsen: RBC réitère son opinion 'surperformance', objectif 148 euros
Aug 12, 2025
Ipsen Pharma
IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2025
Aug 12, 2025
Research and Markets
Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players
Aug 12, 2025
EIN Presswire
Non-Surgical Aesthetic Device Market is Projected to Reach USD 6.5 Billion, with a Robust 5.4% CAGR Till 2035
Aug 12, 2025
PR Newswire UK
IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight
Aug 11, 2025
PR Newswire
IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight
Aug 11, 2025
BioSpace
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights
Aug 8, 2025
Sutro Biopharma, Inc.
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights
Aug 7, 2025
Ipsen
Cap sur l’innovation à Dreux : Ipsen inaugure ses nouveaux laboratoires de développement précoce
Jul 31, 2025
Les Echos
Ipsen relève ses objectifs financiers 2025 après un solide premier semestre
Jul 31, 2025
Idéal Investisseur
L'action IPSEN chute de 7,25%
Jul 31, 2025
Investing.com
Ipsen shares fall 6% as guidance raise overshadowed by product misses
Jul 31, 2025
Pharma Letter
Ipsen posts strong second quarter, raises full-year guidance
Jul 31, 2025
Ipsen Pharma
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
Jul 31, 2025
MarketScreener
Ipsen S.A. Reports Earnings Results for the Half Year Ended June 30, 2025
Jul 31, 2025
Ipsen Pharma
Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)
Jul 31, 2025
Morningstar.com
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
Jul 30, 2025
Les Echos
Ipsen: l'UE approuve le Cabometyx contre certaines tumeurs
Jul 25, 2025
Pharma Letter
Ipsen’s Cabometyx secures EC nod for neuroendocrine tumors
Jul 25, 2025
BioSpace
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
Jul 25, 2025
EIN Presswire
Botulinum Toxin Market to Reach USD 13.1 Billion, Globally, by 2031 at 8.6% CAGR: Allied Market Research
Jul 24, 2025
Seeking Alpha
Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors
Jul 24, 2025
Ipsen Pharma
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
Jul 24, 2025
BioSpace
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
Jul 24, 2025
Morningstar.com
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
Jul 24, 2025
MyPharma Editions
Ipsen annonce des changements au sein de son Comité Exécutif
Jul 23, 2025
MarketScreener
Ipsen S.A. Announces New Appointments to Its Executive Committee
Jul 23, 2025
BioSpace
Ipsen announces changes to its Executive Committee
Jul 23, 2025
Pharma Letter
Ipsen announces executive committee changes
Jul 23, 2025
Ipsen Pharma
Ipsen announces changes to its Executive Committee
Jul 23, 2025
Morningstar.com
Ipsen announces changes to its Executive Committee
Jul 22, 2025
Ipsen Pharma
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2025
Jul 22, 2025
Morningstar.com
GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights
Jul 17, 2025
Spherix Global Insights
GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights
Jul 17, 2025
Actu.fr
A Dreux, Ipsen inaugure deux laboratoires de développement précoce, au coeur d'une stratégie mondiale
Jul 12, 2025
prnewswire.co.uk
Botulinum Toxins Market worth $15.7 billion by 2030 with 11.7% CAGR | MarketsandMarkets™
Jul 11, 2025
GlobeNewswire News Room
Ipsen - June 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
Jul 10, 2025
EIN Presswire
Europe Pharmaceutical Drugs Market Expands with R&D Innovation, Biologics Growth, and Regulatory Harmonization 2025–2032
Jul 10, 2025
PR Newswire
The Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal and IRICoR Announce initiation of Phase 1 Trial of Licensed Small Molecule Therapy for Solid Tumors
Jul 8, 2025
Canada NewsWire
The Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal and IRICoR Announce initiation of Phase 1 Trial of Licensed Small Molecule Therapy for Solid Tumors Français
Jul 8, 2025
GlobeNewswire News Room
IPSEN - Buy-back programme - Art 5 of MAR - Week 27- 2025
Jul 8, 2025
BioSpace
Ipsen - Half year statement - 2025 06 30
Jul 8, 2025
GlobeNewswire News Room
Ipsen - Half year statement - 2025 06 30
Jul 7, 2025
vd-communication.fr
Nomination Ipsen : Senior Director, CMC Regulatory Affairs, Biologics
Jul 5, 2025
Ipsen
Ipsen inaugure son nouveau siège social mondial à Paris
Jul 3, 2025
Boursier.com
Ipsen : inaugure son nouveau siège social mondial à Paris
Jul 2, 2025
Ipsen Pharma
IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2025
Jul 1, 2025
EIN Presswire
Neurogenic Detrusor Overactivity Market Forecast To 2034 – For Business Leaders, Analysts, And Strategic Teams
Jul 1, 2025
L'Usine Nouvelle
Dominique Bery, une stratège pour l’activité France d'Ipsen
Jun 28, 2025
Business Wire
Alagille Syndrome Market Research 2025-2035 | Funding Activities, Mergers and Acquisitions, Regulatory Approvals, Partnerships, Collaborations and Business Expansions - ResearchAndMarkets.com
Jun 27, 2025
Ipsen Pharma
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2025
Jun 24, 2025
Research and Markets
Alagille Syndrome Market Research 2025-2035 | Competitive Analysis of Mirum Pharmaceuticals, Ipsen, and Takeda Pharmaceutical
Jun 24, 2025
Boursier.com
Ipsen : avis positif du CHMP pour Cabometyx dans les tumeurs neuroendocrines avancées
Jun 23, 2025
Benzinga.com
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars
Jun 23, 2025
PharmiWeb
Bile Acid Transport Inhibitors (IBATs) Market to Reach $200 Million by 2025, Forecasted to Grow at 20% CAGR Through 2032 Amidst Rising Rare Liver Disease Incidence
Jun 23, 2025
Les Echos
Ipsen se rapproche d'une autorisation en UE pour cabozantinib, son traitement contre certaines tumeurs
Jun 20, 2025
BioSpace
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
Jun 20, 2025